Recombinant Human CD27 Protein，His

CD27 is a member of the Tumor Necrosis Factor Receptor (TNFR) superfamily, playing a crucial role in the regulation of immune responses and T-cell activation. It is primarily expressed on the surface of T-lymphocytes and is involved in various immune functions, including cell proliferation, differentiation, and survival. Research into CD27 has gained momentum due to its potential implications in immunotherapy and the treatment of cancers and autoimmune diseases. The discovery of CD27 as a co-stimulatory molecule has highlighted its importance in enhancing T-cell responses when engaged by its ligand, CD70. This interaction is critical for the survival and clonal expansion of T-cells, making CD27 a promising target for therapeutic intervention. Recombinant CD27 proteins have been developed to study its biological functions in vitro and in vivo, as well as to explore its potential as a biomarker for immune-related diseases. The ability to produce high-quality CD27 recombinant proteins is vital for evaluating their properties and effects in various experimental settings, including cellular assays and therapeutic applications. Investigating CD27 in the context of cancer immunotherapy is particularly appealing, as it may facilitate the enhancement of anti-tumor immune responses and improve the efficacy of existing treatment modalities. Consequently, ongoing research aims to elucidate the mechanisms of CD27 signaling, its interactions with other immune molecules, and its overall impact on the immune landscape, paving the way for innovative strategies to harness this receptor in clinical settings.